Skip to main content
SpringerLink
Log in

Bewertung der Komponenten von Topika

  • Conference paper
Nutzen und Risiko von Kosmetika

  • 223 Accesses

Zusammenfassung

Während Kosmetika Zubereitungen zur Reinigung und Pflege des Körpers darstellen und die Funktion desselben - im strengen Sinn - unbeeinflußt lassen sollen, handelt es sich bei Arzneimitteln um Präparate zur Beeinflussung pathologischer oder physiologischer Körperfunktionen. Daneben zählen aber auch Diagnostika zu den Arzneimitteln.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bamberger CM, Else T, Bamberger A, Beil FU, Schulte HM (1997) Regulation of the human interleu- kin-2 gene by the a and β isoforms of the glucocorticoid receptor. Mol Cell Endocrinol 136: 23–28.

    Article  PubMed  CAS  Google Scholar 

  2. Bollag W (1983) The development of retinoids in experimental and clinical oncology and dermatology. J Am Acad Dermatol 9: 797–805.

    Article  PubMed  CAS  Google Scholar 

  3. Boxman IL, Ruwhof C, Boerman OC, Löwik CW, Ponec M (1996) Role of fibroblasts in the regulation of proinflammatory interleukin IL-1, IL-6 and IL-8 levels induced by keratinocyte-derived IL-1. Arch Dermatol Res 288: 391–398.

    Article  PubMed  CAS  Google Scholar 

  4. Chen Z, Wang ZY, Chen SJ (1997) Acute promyelocytic leukemia: cellular and molecular basis of diffentiation and apoptosis. Pharmacol Ther 76:141–149.

    Article  PubMed  CAS  Google Scholar 

  5. Early E, Dmitrovsky E (1995) Acute promyelocytic leukemia: retinoic acid response and resistance. J Invest Med 43:337–344.

    CAS  Google Scholar 

  6. Elias PM, Williams ML (1981) Retinoids, cancer, and the skin. Arch Dermatol 117:160–180.

    Article  PubMed  CAS  Google Scholar 

  7. Elson ML (1990) Treatment of striae distensae with topical tretinoin. J Dermatol Surg Oncol 16:267–270.

    PubMed  CAS  Google Scholar 

  8. Gilchrest BA (1997) Treatment of photodamage with topical tretinoin: an overview. J Am Acad Dermatol 36: 27–36.

    Article  Google Scholar 

  9. Goldring MB, Goldring SR (1991) Cytokines and cell growth control. Crit Rev Eukar Gen Exp 1:301–329.

    CAS  Google Scholar 

  10. Griffiths CEM, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ (1993) Topical tretinoin (retinoic acid) improves melasma. A vehicle-controlled, clinical trial. Br J Dermatol 129: 415–421.

    Article  PubMed  CAS  Google Scholar 

  11. Griffiths CEM, Kang S, Ellis CN et al. (1995) Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation. Arch Dermatol 131: 1037–1044.

    Article  PubMed  CAS  Google Scholar 

  12. Gysler A, Lange K, Korting HC, Schäfer-Korting M (1997) Prednicarbate biotransformation in human keratinocytes and fibroblasts. Pharm Res 14: 793–797.

    Article  PubMed  CAS  Google Scholar 

  13. Gysler A, Schäfer-Korting M (1998) Biotransformation and permeation of topical glucocorticoids in excised human skin and reconstructed epidermis. Naunyn Schmiedebergs Arch Pharmacol (Suppl) 355: R8,17

    Google Scholar 

  14. Gysler A, Königsmann U, Schäfer-Korting M (1999) Dreidimensionale Hautmodelle zur Erfassung der perkutanen Resorption. Altex 16: 67–72.

    PubMed  Google Scholar 

  15. Kang S, Kim JK, Griffiths CEM et al. (1996) Topical tretinoin (retinoic acid) improves early stretch marks. Arch Dermatol 132: 519–526.

    Article  PubMed  CAS  Google Scholar 

  16. Kochhar DM, Christian MS (1997) Tretinoin: a review of the nonclinical developmental toxicology experience. J Am Acad Dermatol 36: 47–59.

    Article  Google Scholar 

  17. Kupper TS, Groves RW (1995) The interleukin-1 axis and cutaneous inflammation. J Invest Dermatol 105: 62–66.

    Article  Google Scholar 

  18. Lange K, Gysler A, Bader M, Kleuser B, Korting HC, Schäfer-Korting M (1997) Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro. Pharm Res 14: 1744–1749.

    Article  PubMed  CAS  Google Scholar 

  19. Lange K, Bader M, Schäfer-Korting M (1998) Cellular cytokine synthesis: Differential effects of topical glucocorticoids. Naun Schmiedeb Arch Pharmacol, Suppl 357: 325

    Google Scholar 

  20. Marshall Johnson E (1997) A risk assessment of topical tretinoin as a potential human developmental toxin based on animal and comparative human data. J Am Acad Dermatol 36: 86–90.

    Article  Google Scholar 

  21. McMichael AJ, Griffiths CEM, Talwar HS, Finkel LJ, Rafal ES, Hamilton TA, Voorhees JJ (1996) Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 135: 60–64.

    Article  PubMed  CAS  Google Scholar 

  22. Olsen EA, Katz HI, Levine N et al. (1997a) Tretinoin emollient cream for photodamaged skin: Results of 48-week, multicenter, double-blind studies. J Am Acad Dermatol 37: 217–226.

    Article  PubMed  CAS  Google Scholar 

  23. Olsen EA, Katz HI, Levine N et al. (1997b) Sustained improvement in photodamaged skin with reduced tretinoin emollient cream treatment regimen: Effect of once-weekly and three-times-weekly application. J Am Acad Dermatol 37: 227–230.

    Article  PubMed  CAS  Google Scholar 

  24. Orfanos CE, Ehlert R, Gollnick H (1987) The retinoids: a review of their clinical pharmacology and therapeutic use. Drugs 34: 459–503.

    Article  PubMed  CAS  Google Scholar 

  25. Ponec M, Kempenaar J, Shroot B, Caron JC (1986) Glukokorticoids: binding affinity and lipophility. J Pharm Sci 75: 973–975.

    Article  PubMed  CAS  Google Scholar 

  26. Pribanich S, Simpson FG, Held B, Yarbrough CL, White SN (1994) Low-dose tretinoin does not improve striae distensae: a double-blind, placebo-controlled study. Cutis 54:121–124.

    PubMed  CAS  Google Scholar 

  27. Schäfer-Korting M, Korting HC, Kerscher M, Lenhard S (1993) Prednicarbate activity and benefit/ risk ratio in relation to other topical glucocorticoids. Clin Pharmacol Ther 54: 448–456.

    Article  PubMed  Google Scholar 

  28. Schäfer-Korting M, Schmid MH, Korting HC (1996) Topical glucocorticoids with improved risk- benefit ratio. Rationale of a new concept. Drug Safety 14: 375–385.

    Google Scholar 

  29. Schäfer-Korting M, Gysler A (1998) Topical glucocorticoids. In: Korting HC, Schäfer-Korting M (ed) The benefit/risk ratio: a handbook for the rational use of potentially hazardous drugs. CRC, Boca Raton, pp 361–373.

    Google Scholar 

  30. Shapiro L, Pastuszak A, Curto G, Koren G (1997) Safety of first-trimester exposure to topical tretinoin: prospective cohort study. Lancet 350:1143–1144.

    Article  PubMed  CAS  Google Scholar 

  31. Würthwein G, Rehder S, Rohdewald P (1992) Lipophility and Receptor Affinity of Glucocorticoids. Pharm Ztg Wiss 4:161–167.

    Google Scholar 

Download references

Authors
  1. M. Schäfer-Korting
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie, Ludwig-Maximilians-Universität München, Frauenlobstraße 9–11, 80337, München, Germany

    O. Braun-Falco  & H. C. Korting  & 

  2. Hautklinik am Städtischen Klinikum Karlsruhe gGmbH, Moltkestraße 120, 76133, Karlsruhe, Germany

    Max Gloor

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Schäfer-Korting, M. (2000). Bewertung der Komponenten von Topika. In: Braun-Falco, O., Gloor, M., Korting, H.C. (eds) Nutzen und Risiko von Kosmetika. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59747-3_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59747-3_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64108-4

  • Online ISBN: 978-3-642-59747-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation